Journal
VACCINE
Volume 28, Issue 19, Pages 3269-3272Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.vaccine.2010.02.098
Keywords
Human papillomavirus; Oropharyngeal cancer; p16
Categories
Funding
- Diagnostics and Technology Branch of the Australian Government Department of Health and Ageing
- Cure Cancer Foundation Australia and Sydney Head and Neck Cancer Institute
Ask authors/readers for more resources
This study provides Australian data on the incidence of human papillomavirus(HPV)-related oropharyngeal cancer to aid the debate on extending the HPV vaccination programme to males The HPV status for 302 oropharyngeal cancers diagnosed between 1987 and 2006 was determined by HPV E6-targeted multiplex real-time PCR/p16 immunohistochemistry The overall HPV-positivity rate was 36% (94% types 16 and 18). HPV-related cancer increased from 19%(1987-1990) to 47%(2001-2005). HPV data used in conjunction with Australian cancer incidence data 2001-2005 showed that 1 56 cases of oropharyngeal cancer per 100.000 males per year were associated with HPV types targeted by the vaccine Vaccinating males may substantially reduce the burden of oropharyngeal cancer in Australia. (C) 2010 Elsevier Ltd All rights reserved
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
